trending Market Intelligence /marketintelligence/en/news-insights/trending/H1ac-UbglsbLtw-WU4zzjg2 content esgSubNav
In This List

Teva, BioDelivery reach settlement over opioid addiction drug

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector


Teva, BioDelivery reach settlement over opioid addiction drug

Teva Pharmaceutical Industries Ltd. agreed not to sell a generic version of BioDelivery Sciences International Inc.'s opioid addiction treatment as part of a settlement to end a patent litigation against the company.

Teva is barred from marketing a generic version of Bunavail until July 23, 2028.

BioDelivery filed a lawsuit in the U.S. District Court for the District of Delaware after Teva filed an application seeking approval from the U.S. Food and Drug Administration to market a generic version of the drug.

BioDelivery said the abbreviated new drug application infringed on several of its patents.